Cancer Genes, Tumor Suppressors, and Regulation of IGF1-R Gene Expression in Cancer

  • Haim Werner
  • Zohar Attias-Geva
  • Itay Bentov
  • Rive Sarfstein
  • Hagit Schayek
  • Doron Weinstein
  • Ilan Bruchim
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The IGF1-R displays potent antiapoptotic, prosurvival activities and has an important role in cell cycle progression. In addition, activation of the IGF1-R signaling pathway is a crucial prerequisite for malignant transformation. Overexpression of the IGF1-R has been identified as a typical hallmark of many, but definitely not all, types of tumors. The level of expression of the IGF1-R gene is determined by the concerted action of positively acting and negatively acting transcription factors. Loss-of-function mutation of tumor suppressors, a characteristic feature of many human cancers, leads to IGF1-R expression, with ensuing activation of cell-surface receptors by circulating and/or locally produced IGF-1 and IGF-2.

Keywords

Zinc Estrogen Proline Sarcoma Androgen 

Notes

Acknowledgments

Work in the laboratory of H.W. is supported by grants from the Israel Science Foundation, Israel Cancer Association, and Insulin-Dependent Diabetes Trust (IDDT, UK). I.B. wishes to thank the Israel Cancer Research Fund (ICRF, Montreal, Canada) for its generous support.

References

  1. Abramovitch S, Glaser T, Ouchi T, and Werner H (2003) BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett 541: 149  –154.PubMedCrossRefGoogle Scholar
  2. Abramovitch S, and Werner H (2003) Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. Horm Metab Res 35: 758  –762.PubMedCrossRefGoogle Scholar
  3. Aiello A, Pandini G, Sarfstein R, Werner H, Manfioletti G, Vigneri R, and Belfiore A (2010) HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer, in press.Google Scholar
  4. Baserga R (1999) The IGF-I receptor in cancer research. Exp Cell Res 253: 1–  6.PubMedCrossRefGoogle Scholar
  5. Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19: 5574  –5581.PubMedCrossRefGoogle Scholar
  6. Baylin SB, and Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics join genetics. Trends Gen 16: 168  –174.CrossRefGoogle Scholar
  7. Baylin SB, Herman JG, Graff JR, Vertino PM, and Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141–196.PubMedCrossRefGoogle Scholar
  8. Beitner-Johnson D, Werner H, Roberts CT, Jr, and LeRoith D (1995) Regulation of insulin-like growth factor I receptor gene expression by Sp1: Physical and functional interactions of Sp1 at GC boxes and at a CT element. Mol Endocrinol 9: 1147–1156.PubMedCrossRefGoogle Scholar
  9. Bentov I, LeRoith D, and Werner H (2003) Wilms’ tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology 144: 4276–  4279.PubMedCrossRefGoogle Scholar
  10. Bentov I, and Werner H (2004) IGF, IGF receptor and overgrowth syndromes. Ped Endocrinol Rev 1: 352–360.Google Scholar
  11. Bentov I, Narla G, Schayek H, Akita K, Plymate SR, LeRoith D, Friedman SL, and Werner H (2008) Insulin-like growth factor-I regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology 149: 1890  –1897.PubMedCrossRefGoogle Scholar
  12. Bondy CA, Werner H, Roberts CT, Jr, and LeRoith D (1990) Cellular pattern of insulin-like growth factor I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. Mol Endocrinol 4: 1386–1398.PubMedCrossRefGoogle Scholar
  13. Bondy CA, Werner H, Roberts CT, Jr, and LeRoith D (1992) Cellular pattern of Type I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience 46: 909  –923.PubMedCrossRefGoogle Scholar
  14. Bruchim I, Attias Z, and Werner H (2009) Targeting the IGF1 axis in cancer proliferation. Exp Opinion Ther Targets 13: 1179  –1192.CrossRefGoogle Scholar
  15. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, and Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 1367–1373.CrossRefGoogle Scholar
  16. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, and Balk SP (1999) Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of type 1 insulin-like growth factor receptor. Am J Pathol 155: 1271–1279.PubMedCrossRefGoogle Scholar
  17. Conaway RC, and Conaway JW (2002) The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription. Adv Cancer Res 85: 1–12.PubMedCrossRefGoogle Scholar
  18. Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL, and Roberts CT, Jr (2001) Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142: 21–27.PubMedCrossRefGoogle Scholar
  19. Eshet R, Werner H, Klinger B, Silbergeld A, Laron Z, LeRoith D, and Roberts CT, Jr (1993) Up-regulation of insulin-like growth factor-I (IGF-I) receptor gene expression in patients with reduced serum IGF-I levels. J Mol Endocrinol 10: 115–120.PubMedCrossRefGoogle Scholar
  20. Fan S, Wang J, Yuan RQ, Ma Y, Meng Q, Erdos MR, Brody LC, Goldberg ID, and Rosen EM (1998) BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16: 3069–3082.PubMedCrossRefGoogle Scholar
  21. Finkeltov I, Kuhn S, Glaser T, Idelman G, Wright JJ, Roberts CT, Jr, and Werner H (2002) Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein. Oncogene 21: 1890  –1898.PubMedCrossRefGoogle Scholar
  22. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120–122.PubMedCrossRefGoogle Scholar
  23. Gerald WL, and Haber DA (2005) The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Sem Cancer Biol 15: 197–205.CrossRefGoogle Scholar
  24. Gerald WL, Ladanyi M, de Alava E, Cuatrecasas M, Kushner BH, LaQuaglia MP, and Rosai J (1998) Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol 16: 3028–3036.PubMedGoogle Scholar
  25. Harris CC, and Hollstein M (1993) Clinical implications of the p53 tumor suppressor gene. New England J Med 329: 1318–1327.CrossRefGoogle Scholar
  26. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, and Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62: 2942–2950.PubMedGoogle Scholar
  27. Heron-Milhavet L, and LeRoith D (2002) Insulin-like growth factor-I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 277: 15600  –15606.PubMedCrossRefGoogle Scholar
  28. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, and Jensen RA (1996) Growth retardation and tumour inhibition by BRCA1. Nature Gen 12: 298–301.CrossRefGoogle Scholar
  29. Idelman G, Glaser T, Roberts CT, Jr, and Werner H (2003) WT1-p53 interactions in IGF-I receptor gene regulation. J Biol Chem 278: 3474  –3482.PubMedCrossRefGoogle Scholar
  30. Irwin MS, and Kaelin WG (2001) p53 family update: p73 and p63 develop their own identities. Cell Growth Diff 12: 337–349.PubMedGoogle Scholar
  31. Kaplan PJ, Mohan S, Cohen P, Foster BA, and Greenberg NM (1999) The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59: 2203–2209.PubMedGoogle Scholar
  32. Karnieli E, Werner H, Rauscher FJ, III, Benjamin LE, and LeRoith D (1996) The IGF-I receptor gene promoter is a molecular target for the Ewings’ sarcoma-Wilms’ tumor 1 fusion protein. J Biol Chem 271: 19304  –19309.PubMedCrossRefGoogle Scholar
  33. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, and Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708–1711.PubMedCrossRefGoogle Scholar
  34. Kim SY, Toretsky JA, Scher D, and Helman LJ (2009) The role of IGF-1R in pediatric malignancies. Oncologist 14: 83–91.PubMedCrossRefGoogle Scholar
  35. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, et al (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10: 2918–2921.PubMedCrossRefGoogle Scholar
  36. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, and Yee D (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13: 787–796.PubMedCrossRefGoogle Scholar
  37. LeRoith D, and Helman LJ (2004) The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 5: 403.CrossRefGoogle Scholar
  38. Li L-C, Okino ST, and Dahiya R (2004) DNA methylation in prostate cancer. Biochim et Biophys Acta 1704: 87–102.Google Scholar
  39. Li LC, Chui R, Nakajima K, Oh BR, Au HC, and Dahiya R (2000) Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 60: 702–706.PubMedGoogle Scholar
  40. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, and Mayer D (2005) Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Human Pathol 36: 1186  –1196.CrossRefGoogle Scholar
  41. Lin HK, Yeh S, Kang HY, and Chang C (2001) Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98: 7200–7205.PubMedCrossRefGoogle Scholar
  42. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, and Papa MZ (2006) Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 191: 605  –612.PubMedCrossRefGoogle Scholar
  43. Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW, Mayer D, and Werner H (2007a) Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm Metab Res 39: 179  –185.PubMedCrossRefGoogle Scholar
  44. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, and Werner H (2007b) Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Letters 257: 236  –243.PubMedCrossRefGoogle Scholar
  45. Maor SB, Abramovitch S, Erdos MR, Brody LC, and Werner H (2000) BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Gen Metab 69: 130  –136.CrossRefGoogle Scholar
  46. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66  –71.PubMedCrossRefGoogle Scholar
  47. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Liberman TA, et al (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221–230.PubMedCrossRefGoogle Scholar
  48. Nahor I, Abramovitch S, Engeland K, and Werner H (2005) The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Hormone IGF Res 15: 388–396.CrossRefGoogle Scholar
  49. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, and Lee AV (2001) Re-expression of estrogen receptor a in estrogen receptor a-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 61: 5771–5777.PubMedGoogle Scholar
  50. Oren M (1992) p53: The ultimate tumor suppressor gene? FASEB J 6: 3169–3176.PubMedGoogle Scholar
  51. Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SAW, Ramasharma K, Marshall M, and Li CH (1989) Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3: 1701–1709.PubMedCrossRefGoogle Scholar
  52. Pandini G, Mineo R, Frasca F, Roberts CT, Jr, Marcelli M, Vigneri R, and Belfiore A (2005) Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65: 1849  –1857.PubMedCrossRefGoogle Scholar
  53. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev Cancer 8: 915–928.CrossRefGoogle Scholar
  54. Pollak MN (2004) Insulin-like growth factors and neoplasia. Novartis Found Symp 262: 84  –98.PubMedCrossRefGoogle Scholar
  55. Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372: 143  –149.PubMedCrossRefGoogle Scholar
  56. Rajski M, Zanetti-Dallenbach R, Vogel B, Hermann R, Rochlitz C, and Buess M (2010) IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med 8: 1.PubMedCrossRefGoogle Scholar
  57. Renehan AG, Zwahlen M, C M, O’Dwyer ST, Shalet SM, and Egger M (2004) Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346  –1353.Google Scholar
  58. Rubinstein M, Idelman G, Plymate SR, Narla G, Friedman SL, and Werner H (2004) Transcriptional activation of the IGF-I receptor gene by the Kruppel-like factor-6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology 145: 3769–3777.PubMedCrossRefGoogle Scholar
  59. Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, and Surmacz E (1999) Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 81: 299–304.PubMedCrossRefGoogle Scholar
  60. Samani AA, Yakar S, LeRoith D, and Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Rev 28: 20–  47.CrossRefGoogle Scholar
  61. Sarfstein R, Belfiore A, and Werner H (2010) Identification of insulin-like growth factor-I receptor gene promoter-binding proteins in estrogen receptor (ER)-positive and ER-depleted breast cancer cells. Cancers 2: 233  –261.CrossRefGoogle Scholar
  62. Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, Ginsberg D, Plymate SR, and Werner H (2010a) Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor gene. Growth Hormone IGF Res 20: 68  –72.CrossRefGoogle Scholar
  63. Schayek H, Bentov I, Sun S, Plymate SR, and Werner H (2010b) Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res 316: 1479  –1488.PubMedCrossRefGoogle Scholar
  64. Schayek H, Haugk K, Sun S, True LD, Plymate SR, and Werner H (2009) Tumor suppressor BRCA1 is expressed in prostate cancer and controls IGF1-R gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 15: 1558  –1565.PubMedCrossRefGoogle Scholar
  65. Schayek H, Seti H, Greenberg NM, Werner H, and Plymate SR (2010c) Differential regulation of IGF1-R gene transcription by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol 323: 239–245.PubMedCrossRefGoogle Scholar
  66. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, and Mayer D (2000) Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89: 506  –513.PubMedCrossRefGoogle Scholar
  67. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, et al (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65: 3868–3876.PubMedCrossRefGoogle Scholar
  68. Scotlandi K, and Picci P (2008) Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opinion Oncol 20: 419–  427.CrossRefGoogle Scholar
  69. Sell C, Rubini M, Rubin R, Liu J-P, Efstratiadis A, and Baserga R (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90: 11217–11221.PubMedCrossRefGoogle Scholar
  70. Shi R, Yu H, McLarty J, and Glass J (2004) IGF-I and breast cancer: a meta analysis. Int J Cancer 111: 418–  423.PubMedCrossRefGoogle Scholar
  71. Stewart AJ, Johnson MD, May FEB, and Westley BR (1990) Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen stimulated proliferation of human breast cancer cells. J Biol Chem 265: 21172–21178.PubMedGoogle Scholar
  72. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, and Greenberg NM (2008) Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 68: 3495–3504.PubMedCrossRefGoogle Scholar
  73. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, and Plymate SR (1996) Protein and mRNA for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81: 3774–3782.PubMedCrossRefGoogle Scholar
  74. Voskuil DW, Bosma A, Vrieling A, Rookus MA, and van’t Veer LJ (2004) Insulin-like growth factor system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 84: 225–233.Google Scholar
  75. Wang Q, Zhang H, Fishel R, and Greene MI (2000) BRCA1 and cell signaling. Oncogene 19: 6152–6158.PubMedCrossRefGoogle Scholar
  76. Werner H (2009) The pathophysiological significance of IGF-I receptor overexpression: new insights. Ped Endocrinol Rev 7: 2–5.Google Scholar
  77. Werner H, Bach MA, Stannard B, Roberts CT, Jr, and LeRoith D (1992) Structural and functional analysis of the insulin-like growth factor I receptor gene promoter. Mol Endocrinol 6: 1545  –1558.PubMedCrossRefGoogle Scholar
  78. Werner H, and Bruchim I (2010) Basic and clinical significance of IGF-1-induced signatures in cancer. BMC Med 8: 2.PubMedCrossRefGoogle Scholar
  79. Werner H, Karnieli E, Rauscher FJ, III, and LeRoith D (1996) Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93: 8318–8323.PubMedCrossRefGoogle Scholar
  80. Werner H, and LeRoith D (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68: 183  –223.PubMedCrossRefGoogle Scholar
  81. Werner H, and Maor S (2006) The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab 17: 236  –242.PubMedCrossRefGoogle Scholar
  82. Werner H, Rauscher FJ, III, Sukhatme VP, Drummond IA, Roberts CT, Jr, and LeRoith D (1994) Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 269: 12577–12582.PubMedGoogle Scholar
  83. Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ, III, Sens DA, Garvin AJ, LeRoith D, and Roberts CT, Jr (1993) Increased expression of the insulin-like growth factor-I receptor gene, IGFIR, in Wilms’ tumor is correlated with modulation of IGFIR promoter activity by the WT1 Wilms’ tumor gene product. Proc Natl Acad Sci USA 90: 5828  –5832.PubMedCrossRefGoogle Scholar
  84. Werner H, and Roberts CT, Jr (2003) The IGF-I receptor gene: a molecular target for disrupted transcription factors. Genes, Chromosomes & Cancer 36: 113–120.CrossRefGoogle Scholar
  85. Werner H, Shen-Orr Z, Rauscher FJ, III, Morris JF, Roberts CT, Jr, and LeRoith D (1995) Inhibition of cellular proliferation by the Wilms’ tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15: 3516  –3522.PubMedGoogle Scholar
  86. Werner H, Woloschak M, Adamo M, Shen-Orr Z, Roberts CT, Jr, and LeRoith D (1989) Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 86: 7451–7455.PubMedCrossRefGoogle Scholar
  87. Wiesener MS, Maxwell PH, and Eckardt KU (2009) New insights into the role of the tumor suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst repression. J Mol Med 87: 871–877.PubMedCrossRefGoogle Scholar
  88. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, and Plymate SR (2006) Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99: 392–  401.PubMedCrossRefGoogle Scholar
  89. Yang A, and McKeon F (2000) P63 and p73: p53 mimics, menaces and more. Nature Rev 1: 199  –207.CrossRefGoogle Scholar
  90. Yee D, and Lee AV (2000) Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mamm Gland Biol Neoplasia 5: 107–115.CrossRefGoogle Scholar
  91. Yuen JSP, Cockman ME, Sullivan M, Protheroe A, Turner GDH, Roberts IS, Pugh CW, Werner H, and Macaulay VM (2007) The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26: 6499  –  6508.PubMedCrossRefGoogle Scholar
  92. Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN, Fornace AJ, Seth P, and Helman LJ (1996) Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res 56: 1367–1373.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Haim Werner
    • 1
  • Zohar Attias-Geva
    • 1
  • Itay Bentov
    • 1
  • Rive Sarfstein
    • 1
  • Hagit Schayek
    • 1
  • Doron Weinstein
    • 1
  • Ilan Bruchim
    • 1
  1. 1.Department of Human Molecular Genetics and Biochemistry, Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations